SCHEMBL25337261

SCHEMBL25337261

O=Nc1cccc(-c2ccnc(Nc3ccc(C(F)(F)F)cc3)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 5/20 0.53
SYK P43405 1/20 0.53
CDK2 P24941 2/20 0.50
CLK1 P49759 1/20 0.50
CLK2 P49760 1/20 0.50
DYRK1A Q13627 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
IKBKB O14920 2/20 0.49
CHUK O15111 1/20 0.49
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CDK5 Q00535 1/20 0.47
KMT2A Q03164 1/20 0.47
CDK5R1 Q15078 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCD Q05655 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30554508 1.00 PLK1 (0.53) PLK1SYKCDK2CLK1CLK2
SCHEMBL30554555 0.92 PLK1 (0.54) PLK1SYKCDK2CLK1CLK2
SCHEMBL25979971 0.92 PLK1 (0.54) PLK1SYKCDK2CLK1CLK2
SCHEMBL25339601 0.92 PLK1 (0.54) PLK1SYKCDK2CLK1CLK2
SCHEMBL27446988 0.87 CDK2 (0.52) PLK1SYKCDK2CLK1CLK2
SCHEMBL2944816 0.87 CLK1 (0.60) PLK1SYKCDK2CLK1CLK2
SCHEMBL30554478 0.83 PLK1 (0.72) PLK1SYKCDK2CLK1CLK2
SCHEMBL25337631 0.83 PLK1 (0.72) PLK1SYKCDK2CLK1CLK2
SCHEMBL2946515 0.83 PLK1 (0.77) PLK1SYKCDK2CLK1CLK2
SCHEMBL25338424 0.81 MAPK8 (0.49) PLK1SYKABL1PRKCAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2026-01-22 US disclosed
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2025-07-29 US disclosed
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2024-12-17 US disclosed
EP-4472953-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF Nexys Therapeutics, Inc. (US) 2024-12-11 EP disclosed
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-08-22 US disclosed
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed
WO-2023150197-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed
WO-2023150197-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 PLK1 4810/4885SYK 3388/4885CDK2 3767/4885
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, NR1H4, CNR1 PLK1 4850/4885SYK 3947/4885CDK2 3827/4885
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 PLK1 4810/4885SYK 3388/4885CDK2 3767/4885
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 PLK1 4810/4885SYK 3388/4885CDK2 3767/4885
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 PLK1 4810/4885SYK 3388/4885CDK2 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.